GuideNephrology
Rising creatinine or hyperkalaemia after starting ACE inhibitors or ARBs
Summarises who is at higher risk of creatinine and potassium abnormalities when starting an ACE inhibitor or ARB, and how to monitor.
Updated 3 November 2026
When to use it
When starting or up-titrating an ACE inhibitor or ARB, to decide how intensively to monitor labs.
What the studies show
• Parikh 2020 (Kaiser Permanente Northern California and Ontario): checking creatinine and potassium within 30 days of starting an ACE inhibitor or ARB was not associated with lower 30-day mortality. They developed and externally validated a score predicting abnormally high potassium (AUC 0.75) and abnormally high creatinine (AUC 0.62), both well calibrated.
• SCREAM 2017 (Stockholm): potassium > 5.5 mmol/L in the first year was uncommon (1.7%); risk exceeded that of beta-blockers only with filtration < 60 mL/min/1.73 m².
Keep reading in the app
- Risk factors
- How to monitor (KDIGO 2024)
Practical tip
A creatinine rise of up to 30% is expected and does not require stopping the drug.
2 more practical tips in the app.
Reference
- Parikh RV, Nash DM, Brimble KS, et al. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations. Circ Cardiovasc Qual Outcomes. 2020;13(9):e006415.
- Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6(7):e005428.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
